Study Assesses Natera's DiGeorge Syndrome NIPT Screening Test in More Than 20,000 Cases | GenomeWeb

NEW YORK (GenomeWeb) – Analyzing results from more than 20,000 clinical samples, researchers at Natera and their collaborators have found that noninvasive prenatal screening for DiGeorge syndrome, also known as 22q11.2 deletion syndrome, classified almost 0.5 percent of cases as high risk, among them at least 11 true cases but also at least 50 false positives.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.